Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832572 · ClinicalTrials.gov registry record · Phase 4
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
A Phase 4 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00832572 is a Phase 4 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 5 participants.
The verdict
NCT00832572, a Phase 4 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00832572
The ClinicalTrials.gov registry entry for NCT00832572 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00832572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00832572 about?
NCT00832572 is a clinical study titled "Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy". This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinde...
What is the current status of trial NCT00832572?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2009-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00832572?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT00832572?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.